Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(06): 400-407
DOI: 10.1055/s-0042-124421
Article
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

Fang Li
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, China
,
Jiachao Chen
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, China
,
Fei Leng
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, China
,
Zhiqiang Lu
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, China
,
Yan Ling
1   Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, China
› Author Affiliations
Further Information

Publication History

received 09 October 2016
revised 20 December 2016

accepted 21 December 2016

Publication Date:
13 April 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background

Endothelial dysfunction is associated with the risk of cardiovascular complications in diabetic patients. Endothelial progenitor cells (EPCs) and flow-mediated dilation (FMD) are common markers of endothelial function. In this study, we aim to investigate whether the DPP-4 inhibitor saxagliptin modulate EPCs number and FMD in newly diagnosed, treatment-naive type 2 diabetic patients.

Methods

This was a controlled, randomized, open-label clinical trial. Saxagliptin group and metformin group consumed either saxagliptin 5 mg per day or metformin 1 500 mg per day respectively for 12 weeks. Changes of FMD and EPCs number after 12-week intervention were the primary endpoints.

Results

31 patients were initially enrolled and randomized to saxagliptin group (n=16) and metformin group (n=15). 27 patients completed the trial (saxagliptin group n=14 and metformin group n=13), and 4 patients dropped out during the study. FMD and EPCs number increased significantly in both saxagliptin group and metformin group, and there was no significant difference between groups. 2-h postprandial plasma glucose, HbA1c and diastolic blood pressure improved significantly in both groups, and there was no significant difference between groups.

Conclusion

Saxagliptin and metformin had comparable beneficial effects on endothelial function.

Key words

type 2 diabetes - endothelial progenitor cell - flow-mediated dilation - dipeptidyl peptidase-4 inhibitor - saxagliptin
 

  • References

  • 1 Bertoluci MC, Ce GV, da Silva AMV. et al. Endothelial dysfunction as a predictor of cardiovascular disease in type 1 diabetes. World J Diabetes 2015; 6: 679-692
    CrossrefPubMedGoogle Scholar
  • 2 Menegazzo L, Albiero M, Avogaro A. et al. Endothelial progenitor cells in diabetes mellitus. Biofactors 2012; 38: 194-202
    CrossrefPubMedGoogle Scholar
  • 3 Asahara T, Murohara T, Sullivan A. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967
    CrossrefPubMedGoogle Scholar
  • 4 Maiorino MI, Della Volpe E, Olita L. et al. Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. Endocrine 2015; 48: 342-345
    CrossrefPubMedGoogle Scholar
  • 5 Chen LL, Liao YF, Zeng TS. et al. Number and function of circulating endothelial progenitor cell in diabetics with different vascular complications. Zhonghua yi xue za zhi 2009; 89: 1234-1239
    PubMedGoogle Scholar
  • 6 Fadini GP, Miorin M, Facco M. et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-1457
    CrossrefPubMedGoogle Scholar
  • 7 Fadini GP, Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab 2010; 12: 570-583
    CrossrefPubMedGoogle Scholar
  • 8 Georgescu A. Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy. World J Diabetes 2011; 2: 92-97
    CrossrefPubMedGoogle Scholar
  • 9 Tepper OM, Galiano RD, Capla JM. et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786
    CrossrefPubMedGoogle Scholar
  • 10 Liao YF, Chen LL, Zeng TS. et al. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med 2010; 15: 279-285
    CrossrefPubMedGoogle Scholar
  • 11 Siasos G, Zografos T, Oikonomou E. et al. Flow-mediated dilation: is it just a research tool or a useful biomarker for cardiovascular prognosis. Int J Cardiol 2015; 180: 154-157
    CrossrefPubMedGoogle Scholar
  • 12 Quinaglia T, Matos-Souza JR, Feinstein SB. et al. Flow-mediated dilation: An evolving method. Atherosclerosis 2015; 241: 143-144
    CrossrefPubMedGoogle Scholar
  • 13 Yeboah J, Folsom AR, Burke GL. et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009; 120: 502-509
    CrossrefPubMedGoogle Scholar
  • 14 McLenachan JM, Williams JK, Fish RD. et al. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991; 84: 1273-1278
    CrossrefPubMedGoogle Scholar
  • 15 Balestrieri ML, Servillo L, Esposito A. et al. Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation. Diabetologia 2013; 56: 162-172
    CrossrefPubMedGoogle Scholar
  • 16 Li H, Zhang X, Guan X. et al. Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol 2012; 11: 46
    CrossrefPubMedGoogle Scholar
  • 17 Lev EI, Singer J, Leshem-Lev D. et al. Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes. Eur J Prev Cardiol 2014; 21: 1153-1162
    CrossrefPubMedGoogle Scholar
  • 18 Yiu KH, Tse HF. Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell characteristics and function. Arterioscler Thromb Vasc Biol 2014; 34: 1136-1143
    CrossrefPubMedGoogle Scholar
  • 19 Eriksson L, Erdogdu O, Nystrom T. et al. Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. Cardiovasc Diabetol 2012; 11: 27
    CrossrefPubMedGoogle Scholar
  • 20 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865
    CrossrefPubMedGoogle Scholar
  • 21 Fadini GP, Boscaro E, Albiero M. et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes care 2010; 33: 1607-1679
    CrossrefPubMedGoogle Scholar
  • 22 Nakamura K, Oe H, Kihara H. et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014; 13: 110
    CrossrefPubMedGoogle Scholar
  • 23 American Diabetes A . Standards of medical care in diabetes – 2014. Diabetes care 2014; 37 (Suppl. 01) S14-S80
    CrossrefPubMedGoogle Scholar
  • 24 Corretti MC, Anderson TJ, Benjamin EJ. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265
    PubMedGoogle Scholar
  • 25 Poncina N, Albiero M, Menegazzo L. et al. The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. Cardiovasc Diabetol 2014; 13: 92
    CrossrefPubMedGoogle Scholar
  • 26 Han BLL, Zhang L, Fan Z. Effect of DPP-4 inhibitor saxagliptin on endothelium dependent vasodilation in patients with type 2 diabetes. Journal of Shanxi Medical University 2014; 45: 291-294
    PubMedGoogle Scholar
  • 27 van Poppel PC, Netea MG, Smits P. et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes care 2011; 34: 2072-2077
    CrossrefPubMedGoogle Scholar
  • 28 Vitale C, Mercuro G, Cornoldi A. et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005; 258: 250-256
    CrossrefPubMedGoogle Scholar
  • 29 Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350
    CrossrefPubMedGoogle Scholar
  • 30 Hortenhuber T, Rami-Mehar B, Satler M. et al. Endothelial progenitor cells are related to glycemic control in children with type 1 diabetes over time. Diabetes care 2013; 36: 1647-1653
    CrossrefPubMedGoogle Scholar
  • 31 Nystrom T, Gutniak MK, Zhang Q. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215
    CrossrefPubMedGoogle Scholar
  • 32 Irace C, De Luca S, Shehaj E. et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 2013; 10: 72-77
    CrossrefPubMedGoogle Scholar
  • 33 Basu A, Charkoudian N, Schrage W. et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-E1295
    CrossrefPubMedGoogle Scholar
  • 34 Ceriello A, Novials A, Ortega E. et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes care 2013; 36: 2346-2350
    CrossrefPubMedGoogle Scholar
  • 35 Oikonomou D, Kopf S, von Bauer R. et al. Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, 3-arm unicenter study. Cardiovasc Diabetol 2014; 13: 137
    CrossrefPubMedGoogle Scholar
  • 36 Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 2013; 229: 23-29
    CrossrefPubMedGoogle Scholar
  • 37 Liu ZJ, Tian R, Li Y. et al. SDF-1alpha-induced dual pairs of E-selectin/ligand mediate endothelial progenitor cell homing to critical ischemia. Sci Rep 2016; 6: 34416
    CrossrefPubMedGoogle Scholar
  • 38 Gallagher KA, Liu ZJ, Xiao M. et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117: 1249-1259
    CrossrefPubMedGoogle Scholar
  • 39 Zheng H, Shen CJ, Qiu FY. et al. Stromal cell-derived factor 1alpha reduces senescence of endothelial progenitor subpopulation in lectin-binding and DiLDL-uptaking cell through telomerase activation and telomere elongation. J Cell Physiol 2010; 223: 757-763
    PubMedGoogle Scholar
  • 40 Shen X, Zhou Y, Bi X. et al. Stromal cell-derived factor-1alpha prevents endothelial progenitor cells senescence and enhances re-endothelialization of injured arteries via human telomerase reverse transcriptase. Cell Biol Int 2015; 39: 962-971
    CrossrefPubMedGoogle Scholar
  • 41 Hiesinger W, Frederick JR, Atluri P. et al. Spliced stromal cell-derived factor-1alpha analog stimulates endothelial progenitor cell migration and improves cardiac function in a dose-dependent manner after myocardial infarction. J Thorac Cardiovasc Surg 2010; 140: 1174-1180
    CrossrefPubMedGoogle Scholar
  • 42 Connelly KA, Advani A, Zhang Y. et al. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1alpha. J Diabetes 2016; 8: 63-75
    CrossrefPubMedGoogle Scholar